HLA B7 antibody

Catalog No. ABIN1027673

Product Details anti-HLA B7 Antibody

Target: HLA B7 (HLA Class I B7 Alpha (HLA B7))

Reactivity: Human, Non-Human Primate

Host: Mouse

Clonality: Monoclonal

Conjugate: This HLA B7 antibody is un-conjugated

Application: Flow Cytometry (FACS)

Specificity: The mouse monoclonal antibody BB7.1 recognizes an extracellular antigen of HLA-B7 antigen. Although highly specific, it can cross-react with HLA-B42 antigen.

Cross-Reactivity (Details): Human, Non-Human Primates

Purification: Purified by protein-A affinity chromatography.

Purity: > 95 % (by SDS-PAGE)

Immunogen: Papain solubilised HLA-A2, B7

Clone: BB7-1

Isotype: IgG1

Application Details

Application Notes: Flow cytometry: Recommended dilution: 1-4 μg/mL.

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Do not freeze.

Storage: 4 °C

Storage Comment: Store at 2-8°C. Do not freeze.

References for anti-HLA B7 antibody (ABIN1027673)

Cortez-Gonzalez, Sidney, Adotevi, Sette, Millard, Lemonnier, Langlade-Demoyen, Zanetti: "Immunogenic HLA-B7-restricted peptides of hTRT." in: International immunology, Vol. 18, Issue 12, pp. 1707-18, (2006) (PubMed).

de la Salle, Saulquin, Mansour, Klayme, Fricker, Zimmer, Cazenave, Hanau, Bonneville, Houssaint, Lefranc, Naman: "Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP)." in: Clinical and experimental immunology, Vol. 128, Issue 3, pp. 525-31, (2002) (PubMed).

Rini, Selk, Vogelzang: "Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 5, Issue 10, pp. 2766-72, (1999) (PubMed).

Trapani, Vaughan, Tait, McKenzie: "Immunoradiometric assay for the rapid detection of HLA-B27." in: Immunology and cell biology, Vol. 66 ( Pt 3), pp. 215-9, (1991) (PubMed).

Storkus, Alexander, Payne, Dawson, Cresswell: "Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 86, Issue 7, pp. 2361-4, (1989) (PubMed).

Target Details for HLA B7

Target: HLA B7 (HLA Class I B7 Alpha (HLA B7))

Alternative Name: HLA-B7 (HLA B7 Products)

Synonyms: AS antibody, HLAB antibody, SPDA1 antibody, major histocompatibility complex, class I, B antibody, HLA-B antibody

Background: HLA-B7 allele of human HLA class I major histocompatibility (MHC) antigen indicates higher risk of breast cancer and cervical cancer. Expression of HLA-B7 together with HLA-B27 is associated with increased susceptibility to spondyloarthropaties. Flow cytometry detection of these two alleles is being used to screen for patients, who suffer from inflammatory disorders affecting the sacroiliac and intervertebral joints, such as ankylosing spondylosis (AS). The HLA-B7 antigen (11 alleles) is expressed in 22 % of healthy Caucasian individuals.

Pathways: Human Leukocyte Antigen (HLA) in Adaptive Immune Response